Jiale Sun

Jiale Sun

Auto-generated profile, based on publicly available information

Jiale Sun

Department of Urology, The Fourth Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2019 in Urologia Internationalis
Verified
Journal Article
Closed access
PDF file
JSJiaLe Sun
JiaLe Sun
JXJiangNan Xu
JiangNan Xu
JOJun Ouyang
Jun Ouyang
Objective: To investigate the potential risk factors of infectious complications following ureteroscopy (URS). Materials and Methods: Studies reporting risk factors of infectious complications following URS were searched via PubMed, EMBASE, Cochrane Library, and Web of Science databases up to August 30, 2019. OR or mean difference (MD) with 95% CI was calculated to assess the potential risk factors. Results: A total of 14 studies containing 9,532 patients were included. Positive preoperative urine culture was the most significant risk factor (OR 2.95, 95% CI 1.96–4.43, p < 0.01), followed by female gender (OR 1.95, 95% CI 1.48–2.57, p < 0.01), diabetes mellitus (OR 1.55, 95% CI 1.13–2.13, p < 0.01), pre- and postoperative stent (OR 1.53, 95% CI 1.11–2.11, p = 0.01, OR 1.44, 95% CI 1.01–2.03, p = 0.04, relatively), and extended operative time (MD –11.54, 95% CI –16.10 to 6.98, p < 0.01). Age (MD –2.59, 95% CI –5.36 to 0.18, p = 0.07), cumulative stone diameter (MD –1.54; 95% CI –4.63 to 1.55, p = 0.33), and renal insufficiency (OR 1.22, 95% CI 0.80–1.88, p = 0.36) were not the potential risk factors. Conclusion: The prevalence of infectious complications following URS was correlated with female gender, diabetes mellitus, preoperative urine culture, pre- and postoperative stent insertion, and extended operative time. Publication bias and high heterogeneity were observed in some risk factors. Further studies are warranted for a valid conclusion.

31 July 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MYMan Yang
Man Yang
JSJiale Sun
Jiale Sun
LLLiqiong Liu
Liqiong Liu
KXKONG XIANGYI
KONG XIANGYI
DLDongcai Lin
Dongcai Lin
JGJidong Gao
Jidong Gao
Human Epidermal Growth Factor Receptor-2 (HER2)-negative breast cancers (BCs) contain HER2-low and HER2-zero ones. HER2-low breast cancer has been receiving wide-spread concerns as the marvelous effect of novel anti-HER2 antibody-drug conjugates, however, the characteristic remains unknown. Our aim was to explore the differences of clinicopathological indicators and survival outcomes between HER2-low and HER2-0 breast cancers. We retrospectively analyzed 501 invasive breast cancer patients with complete data on HER2 status from 2017 to 2021 in our single center, of whom 415 HER2 negative patients were included for subsequent analysis. Each cohort was further divided into hormone receptor (HR) positive and HR negative subgroup. Clinicopathological factors and survival outcomes were collected and compared between HER2-low BCs and HER2-0 BCs. HER2-low BCs was obviously higher in HR positive BCs, with 277 (90.5%) HER2-low HR positive patients, 29 (9.5%) HER2-low HR negative patients, 68 (62.4%) HER2-0 HR positive patients and 41 (37.6%) HER2-0 HR negative patients (P < 0.001). Significant differences between HER2-low BCs and Her2-0 BCs were observed in lymph node ratio (LNR) (mean rank, 215 vs. 188 P = 0.014), estrogen receptor (ER)expression (90.5% vs. 62.4% P < 0.001), progesterone receptor (PR) expression (84.3% vs. 56.9% P < 0.001), Ki-67 expression (46.4% vs. 61.5% P < 0.001), androgen receptor (AR) expression (68% vs. 50.5% P < 0.001), adjuvant chemotherapy (69% vs. 79.8% P = 0.03). HER2-low BCs had lower histological grade than HER2-0 BCs, with grade I–II (68.7% vs. 43.1%) and grade III (22.2% vs. 43.1%) P < 0.01. No statistical differences were detected between the two groups for DFS and DDFS. Our results demonstrated that HR and AR status was closely related to HER2-low breast cancers. Further exploration about survival prognosis of HER2-low breast cancer is badly needed.

1 September 2021 in International Journal of General Medicine
Verified
Journal Article
Open access
PDF file
JSJiale Sun
Jiale Sun
XWXuedong Wei
Xuedong Wei
JYJiawei You
Jiawei You
WYWenchang Yue
Wenchang Yue
JOJun Ouyang
Jun Ouyang
JHJianquan Hou
Jianquan Hou
Background: Stanniocalcin-1 (STC1) is a well-studied oncogene that promotes different types of cancer progression. However, the expression status of STC1, the values of STC1 on prognosis, and its immune characteristic in bladder cancer (BLCA) have not been well examined. Methods: The expression of STC1 and its clinicopathological as well as immune characteristics in BLCA samples were firstly identified in The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) databases. Immunohistochemistry (IHC) performed on the tissue microarray (TMA) slide was further used to validate the expression of STC1 and its relationship with immune features in 16 non-muscle invasive bladder cancer (NMIBC) samples and 42 muscle invasive bladder cancer (MIBC) samples. Results: The expression of STC1 was upregulated in higher stage BLCA. High STC1 expression also predicted poor prognosis in BLCA. Subsequently, the TMA validated the expression and prognostic value of STC1 in BLCA. Bioinformatics analysis demonstrated that STC1 and common immune checkpoints as well as immune markers of various immune cells were positively correlated in TCGA. In addition, IHC data from the TMA further validated that tumor cells with higher STC1 level tended to express higher PDL1 as well as increased infiltration of CD3+ T cells. Conclusion: To our knowledge, this is the first comprehensive study that investigates the clinical and immune characteristics of STC1 in BLCA. It may provide new insight into the function of STC1 in regulating tumor immune microenvironment. Further studies are warranted to uncover the potential mechanisms that mediate STC1 expression and tumor immunity in BLCA.

3 August 2022 in Cancer Medicine
Verified
Journal Article
Open access
CHCan Hu
Can Hu
JSJiale Sun
Jiale Sun
ZXZhenyu Xu
Zhenyu Xu
ZZZhiyu Zhang
Zhiyu Zhang
QZQi Zhou
Qi Zhou
JOJun Ouyang
Jun Ouyang
Objective: To develop and externally validate a novel nomogram in biopsy‐naïve patients with prostate‐specific antigen (PSA) <10 ng/ml and PI‐RADS v2.1 = 3 lesions.Methods: We retrospectively collected 307 men that underwent initial biopsy from October 2015 to January 2022 in Cohort 1 (The First Affiliated Hospital of Soochow University). External cohort (Cohort 2, Kunshan Hospital) included 109 men that met our criteria from July 2016 to June 2021. By Slicer‐3D Software, the volume of all lesions was divided into two subgroups (PI‐RADS v2.1 = 3a and 3b). Logistic regression analysis was performed to screen for variables and construct nomogram by analyzing clinical data from Cohort 1. Receiver operating characteristics curve analysis, calibration plot and decision curve analysis (DCA) were plotted to validate the nomogram in external cohort.Results: A total of 70 (22.8%) patients was diagnosed with prostate cancer in Institution 1. Among them, 34 (11.1%) had clinically significant prostate cancer (csPCa). Age, prostate‐specific antigen density, digital rectal examination, PI‐RADS v2.1 = 3 subgroups (3a and 3b) and apparent diffusion coefficient (ADC, <750 mm2/s) were predictive factors for prostate cancer (PCa) and csPCa. High area under the curve of the nomogram was found in Cohort 1 and Cohort 2 for PCa (0.857 vs. 0.850) and for csPCa (0.896 vs. 0.893). Calibration curves showed excellent agreement between the predicted probability and actual risk for the models in internal and external validation. The DCA demonstrated net benefit of our nomogram.Conclusion: Until now, this is the first nomogram that predicts PCa and csPCa in biopsy‐naïve patients with PSA <10 ng/ml and PI‐RADS v2.1 = 3 lesions. Furthermore, PI‐RADS v2.1 = 3 subgroups were considered to be an independent risk factor in our model. Our nomogram may assist urologists in biopsy decision making for these so‐called “double gray zone” patients.

1 May 2020 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
JSJiaLe Sun
JiaLe Sun
ZZZhiYu Zhang
ZhiYu Zhang
JOJun Ouyang
Jun Ouyang

21 March 2025 in Medicine
Verified
Journal Article
Open access
HZHaoyang Zhang
Haoyang Zhang
HMHaojie Mo
Haojie Mo
PLPeng Li
Peng Li
QZQi Zhou
Qi Zhou
ASand Gang Shen
and Gang Shen
JSJiale Sun
Jiale Sun
Relationships between blood metabolites and urolithiasis have been identified in few previous observational studies, and causality remains uncertain. We tried to examine whether blood metabolites were causally associated with upper and lower urinary stones in this bidirectional Mendelian randomization (MR) study. The causal relationship between 1400 blood metabolites and upper and lower urinary stones was investigated using genome-wide association study data. The primary analysis for causality analysis was the inverse variance weighted method, with 4 other methods used as complementary analyses. Intersection was then conducted to show the shared metabolites between upper and lower urinary tract stones, followed by the MR-Egger intercept test, Cochran Q test, leave-one-out analysis, MR-PRESSO and the linkage disequilibrium score regressions. The metabolic pathway analysis was conducted to identify potential metabolic pathways. Lastly, reverse MR analyses were also performed. We identified 15 metabolites as potential causal predictors of urinary stones in forward MR analyses. These metabolites consisted of 1 azole, 2 carbohydrates, 6 lipids, 1 nucleotide, 1 peptide, 1 urea, and 3 metabolites with unknown chemical properties. Additionally, urinary stones were found to be significantly associated with some of the above metabolites in reverse MR analyses. Metabolic pathway analysis identified several pathways that may be implicated in the development of urolithiasis. This MR study has established a causal relationship between 12 blood metabolites and the risk of upper and lower urinary tract stones. The identification of these blood metabolites provides valuable insights into early screening, prevention, and treatment of urolithiasis.